Skip to main contentSkip to navigationSkip to search

ENDO 2026

Long-term CAM2029 octreotide depot maintains biochemical and symptom control in acromegaly across a 4-week dosing interval and during intervals >28 days: data from the ACROINNOVA 2 trial

Click the material you wish to view

ACROINNOVA 2 IGF-1 stability

Pdf 0.5 MB

ACROINNOVA 2 IGF-1 stability supplementary

Pdf 1.2 MB

See all posters presented at
ENDO 2026

Explore more

Disease areas

Orci tempus mi proin est libero mi eget ut pellentesque.

Congresses

Ac purus quam sollicitudin eget. Dignissim quisque cursus elit eget tellus nunc luctus fringilla adipiscing.